Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$8.91 -1.39%

-$0.26 today

Market cap
$761.36M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.11M

Average 1.02M

Returns on capital

Monte Rosa Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-16.6%

avg -6.6%

ROIC

-13.6%

avg -56.9%

ROA

-8.6%

avg -38.1%

Analysis

ROA is currently the strongest return metric at -8.6% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Markus Warmuth

President, Chief Executive Officer & DirectorUSD 1.08M55585.04K0.90%

Filip Janku

Chief Medical OfficerUSD 833.6K5260.61K0.09%

Phil Nickson

Chief Business & Legal OfficerUSD 833.6K47——

Sharon Townson

Chief Scientific OfficerUSD 644.6K5167.84K0.10%

John C. Castle

Chief Data & Information Officer—5578.50K0.12%

Andrew Funderburk

Chief Investor Relations and Strategy Officer————

Magnus Walter DPHIL

Chief Technology Officer————

Matthew Bowen

Corporate Controller & Principal Accounting Officer—3725.89K0.04%

Jennifer Champoux

Chief Operating Officer—5426.95K0.04%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

37

$4.11M

Net Transaction Value

−$4.11M

Net selling

Most Active

Warmuth Markus

10 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 5, 26

Bowen Matthew

Direct

Sell$137.3
Jul 16, 26

Warmuth Markus

Direct

Sell$220.2K
Jul 15, 26

Champoux Jennifer

Direct

Sell$101.7K
Jul 6, 26

Townson Sharon

Direct

Sell$130.2K
Jul 6, 26

Townson Sharon

Direct

Sell$9.7K
Jun 30, 26

Janku Filip

Direct

Sell$132.5K
Jun 29, 26

Janku Filip

Direct

Sell$137.7K
Jun 29, 26

Manning Anthony M.

Direct

Sell$231.1K
Jun 24, 26

Janku Filip

Direct

Sell$642.7K
Jun 23, 26

Janku Filip

Direct

Sell$239.5K

1–10 of 37

Summary

Insiders reported 0 buys worth $0.00 and 37 sells worth $4.11M over the last 12 months. That adds up to net selling of $4.11M. Warmuth Markus was the most active insider with 10 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+2.3% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +2.3% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Monte Rosa Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GLUE's management, answered from reported figures.

Who manages GLUE?

Monte Rosa Therapeutics, Inc. (GLUE) lists 9 active executives. The top listed executive is Sharon Townson, Chief Scientific Officer.

Are GLUE insiders buying or selling?

Recent insider activity shows net buying of $20.21M.